Screening and evaluation of metabolites binding PRAS40 from Erxian decoction used to treat spinal cord injury
Objective: The PRAS40 is an essential inhibitory subunit of the mTORC1 complex, which regulates autophagy. It has been suggested that Erxian Decoction (EXD) could treat spinal cord injury (SCI) via the autophagy pathway. However, the mechanism of whether EXD acts through PRAS40 remains unclear.Metho...
Main Authors: | Li Lin, Jingchuan Yan, Jin Sun, Jianfeng Zhang, Bo Liao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1339956/full |
Similar Items
-
Vitexicarpin Induces Apoptosis and Inhibits Metastatic Properties via the AKT-PRAS40 Pathway in Human Osteosarcoma
by: Hyung-Mun Yun, et al.
Published: (2024-03-01) -
Erxian decoction inhibits apoptosis by activating Akt1 and repairs spinal cord injury in rats
by: Erliang Li, et al.
Published: (2022-11-01) -
Guilu Erxian glue mitigates oxidative damage in mouse GC-1 spermatogonial cells by inhibiting autophagy via the Keap1/Nrf2 pathway
by: Jin Ding, et al.
Published: (2023-10-01) -
Therapeutic effects of Guilu-Erxian-Glue treatment on oligoasthenospermia: Evidence from network pharmacology, molecular docking, and in vivo experimental validation
by: Jin Ding, et al.
Published: (2022-12-01) -
Quercetin Can Improve Spinal Cord Injury by Regulating the mTOR Signaling Pathway
by: Xichen Wang, et al.
Published: (2022-05-01)